[Zhou Jun] great benefits for pharmaceutical companies: it is deemed that the purchase of drugs is started through consistency evaluation, the cost of enterprises participating in the evaluation may be saved, and the VAT rate may be reduced

Major benefits are deemed to be through the consistency evaluation of drugs, and will be purchased by bidding soon! On March 26, Shaanxi issued a notice to publicize the "pass consistency evaluation varieties" declared and qualified in 2017 public hospital drug centralized purchase in Shaanxi Province, with a total of 18 product specifications At the same time, the platform declaration is required for the undeclared "through consistency evaluation varieties", a total of 6 varieties The key point is that the notice also arranges the purchase of drugs deemed to have passed the consistency evaluation, which is the first step to start the purchase of drugs exempt from the consistency evaluation There are consistent evaluation and encouragement policies in these places On March 26, Zhejiang Province issued the management measures for the award and supplement funds of generic drug consistency evaluation, which clearly defined that the top three pharmaceutical manufacturers in the country who passed the generic drug consistency evaluation will be given a one-time award and supplement of 3 million yuan for each variety, and made clear provisions on the procedures for allocating the award and supplement funds, the use of the award and supplement funds, and the supervision of the award and supplement funds According to the media integration report, at present, there are three types of subsidies to carry out evaluation consistency evaluation in China: 1 Cash subsidy: 500000-600000, the highest one is Bozhou, Anhui Province, with a subsidy of 600000 Most of the subsidies are given at the provincial and municipal levels; 2 Sales subsidies: different sales subsidies will be given at different amounts after passing, and the sales of Fuyang will reach 10 million yuan, and 300000 subsidies will be given; 3 Coordination of be resources: coordination of clinical bases (Beijing, Bengbu), and subsidies will be given according to each approval document for the municipal institutions undertaking the bioequivalence test of drugs in the city after the drugs pass the consistency evaluation（ Chongqing) According to statistics, there are subsidy policies in the whole province: Sichuan, Gansu, Anhui, Fujian, Henan, Jiangxi, Beijing, Chongqing, Guizhou, Ningxia; at the prefecture level, there are subsidy policies: Haikou, Chengdu, Bengbu, Fuyang, Guangzhou, Shaoxing, Bozhou, Xinxiang, Nanchang, Taizhou, Jinan, Weihai, Harbin The National Overseas reference preparation procurement service platform is online, which is expected to reduce the cost of enterprise participation! The National Overseas reference preparation procurement service platform jointly built by the national drug review center, Beijing food and Drug Administration and Beijing Economic and Technological Development Zone Management Committee was launched in Yizhuang, Beijing on July 27 The platform will provide one-stop procurement services such as reference preparation inquiry, demand ordering, overseas purchase and transportation, customs clearance at import port, domestic storage and distribution for domestic pharmaceutical manufacturers, solve the problem of obtaining overseas reference preparation in consistency evaluation, and reduce the cost of enterprise participation in evaluation On March 28, the VAT rate of manufacturing and other industries was reduced to 16% The State Council held an executive meeting and decided to reduce the VAT rate of manufacturing and other industries from 17% to 16% from May 1, 2018, and the VAT rate of transportation, construction, basic telecommunication services and agricultural products from 11% to 10% It is estimated that the VAT rate can be reduced by 240 billion yuan in the whole year Review highlights: in the first quarter, the five Chinese pharmaceutical companies anda were approved by FDA According to the statistics of yaozhi.com, in the first quarter of 2018, China's pharmaceutical companies obtained the approval of the FDA to add another five application numbers, a total of five active ingredients, which are: celecoxib declared by Ouyi, desflurane declared by Shanghai Hengrui, acyclovir declared by Yiling pharmaceutical, naproxen sodium declared by humanpuk, and levetiracetam declared by Hainan Puli Another 26 drugs were included in the priority review On March 28, CDE announced the 27th batch of drug registration application list to be included in the priority review procedure This time, 26 drugs were selected Among them, 12 drugs are new drugs, 9 drugs are new drugs, and the remaining 5 drugs are generic drugs Change of declaration requirements for conformity assessment: can the data of stability test be declared within 6 months? On March 27, CDE issued the draft for comments on adjusting the requirements for application materials of long-term stability research of chemical generic drugs, and planned to adjust the requirements for application materials of new registration classification of chemical drugs (Trial) (2015 No 80) and the requirements for application materials of consistency evaluation of quality and efficacy of chemical generic oral solid preparations (Trial) (2016 No 120) on stability test The requirements for application materials are as follows: when applying for listing and conformity assessment of chemical generic drugs, the application materials shall include at least six-month long-term stability test data of three batches of pilot scale and above samples under the premise that the registered batch production scale meets the requirements Hot spots in the market: in 2017, the profit of biomedical manufacturing industry reached nearly 50 billion yuan, with the fastest growth on March 26 According to the analysis on the economic operation of the pharmaceutical industry in 2017 released by the Industrial Coordination Department of the national development and Reform Commission, the main business income of pharmaceutical enterprises above Designated Size in 2017 was 2982.6 billion yuan, with a year-on-year growth of 12.2%; the total profit was 351.97 billion yuan, with a year-on-year growth of 16.6% Among the eight sub industries, the main business grew the fastest was the processing industry of Chinese herbal medicine, with an annual income of 216.53 billion yuan, an increase of 16.7% year on year; the profit growth was the fastest in the biological medicine manufacturing industry, with a total amount of 49.90 billion yuan, an increase of 26.8% year on year At the meeting of the three pharmaceutical companies, Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Wuxi Pharmaceutical Co., Ltd successfully held the 51st working meeting of China Securities Regulatory Commission on March 27 Only 50 days have passed since the pre disclosure and update of Wuxi apptec's February 6 prospectus According to its prospectus report, Wuxi apptec plans to issue no more than 104.1986 million shares to the public on the Shanghai Stock Exchange, accounting for no less than 10% of the total number of shares after issuance, and plans to raise 5.741 billion yuan It is reported that Beijing Kangchen Pharmaceutical Co., Ltd and Ningbo Tianyi Medical Equipment Co., Ltd were also present at the meeting At present, only Wuxi Pharmaceutical Co., Ltd has held the meeting GlaxoSmithKline and Novartis break up friendly and another $10 billion M & A comes out! On March 27, GlaxoSmithKline announced that it had reached an agreement with Novartis to acquire 36.5% of Novartis' shares in the consumer medical joint venture of both sides for $13 billion After the completion of the transaction, GlaxoSmithKline will realize the sole management of the joint venture, which is expected to become the world's second largest consumer health care enterprise after Johnson & Johnson In response, Novartis chief executive Wan Sihan said: this sale will give us more capital to develop core business, promote shareholder returns and strengthen the ability of M & A 2.3 billion Chinese pharmaceutical companies won the largest cancer drug research and development institution in Italy! On March 28 local time in Milan, Italy, the Chinese joint acquirer, which is a wholly-owned subsidiary of Huaxi Co., Ltd and a related enterprise, Haichen pharmaceutical, as well as the controlling shareholder Cao Yuping, Dongcheng venture capital, Gaoyan venture capital and Eucalyptus capital, completed the acquisition of the world-famous Italian tumor research and development organization nervano Medical Sciences Group S.r.l (NMS) group company 9 The delivery of 0% of the shares amounted to EUR 51 million, and the remaining 10% was held by frrb, the regional government of Lombardy, Milan, Italy The total value of the deal, which includes capital injection, debt restructuring and some of the expected revenue in the first quarter of 2018, is about 300 million euros It is reported that the acquisition will change the current mode of setting up a single R & D Center for multinational pharmaceutical companies in China, and China will have the opportunity to obtain the original innovation resource pool of global anti-tumor drug R & D and pharmaceutical.